Positive Interim Trial Results of Brilacidin for IBD Announced by Cellceutix

Positive Interim Trial Results of Brilacidin for IBD Announced by Cellceutix
Cellceutix announced additional interim positive findings from its ongoing Phase 2a trial evaluating brilacidin (PMX-30063) as a treatment for two types of inflammatory bowel disease (IBD) – ulcerative proctitis and ulcerative proctosigmoiditis (UP/UPS). The proof-of-concept, open-label, dose-escalation trial is designed to evaluate the effectiveness, safety and drug properties of three dosing regimens of brilacidin – 50 mg (cohort A), 100 mg (cohort B), and 200 mg (cohort C) – in patients with active mild to moderate UP/UPS. Three of six patients in the third and final group (cohort C) of the study were enrolled earlier this week and the company anticipates the full study will be completed by the second quarter of 2017, just in time to present it at the 2017 Drug Discovery and Therapy World Congress July 10-13 in Boston. Confirming the results in a previous announcement, all 12 patients in two groups completed treatment with brilacidin and all demonstrated a good response to treatment. The study also met its primary effectiveness endpoint in six patients (three in each group), meaning that at day 42, these patients were in clinical remission. Two others were in partial remission and the remaining four did
Subscribe or to access all post and page content.

One comment

  1. Kathleen Williams says:

    How can I get treatment for my IBS. My doctor will not even refer me to a GI specialist. I am also a celiac.

Leave a Comment

Your email address will not be published. Required fields are marked *